Interleukin 6 (IL6) level is a biomarker for functional disease progression within IL6R<sup>358</sup>Ala variant groups in amyotrophic lateral sclerosis patients
Marlena Wosiski‐Kuhn, James B. Caress, Michael S. Cartwright, Gregory A. Hawkins, Carol Milligan
Abstract
Ala variant and thus that any IL6-targeted therapeutic approaches may be more advantageous when aimed at this group. Specifically, with relation to respiratory decline, these patients may benefit from closer respiratory follow-up and early initiation of noninvasive ventilation.
Topics & Concepts
Amyotrophic lateral sclerosisPathologicalInterleukin 6MedicineRespiratory systemBiomarkerDiseaseInternal medicinePulmonary function testingOncologyCytokineBiologyBiochemistryAmyotrophic Lateral Sclerosis ResearchNeurogenetic and Muscular Disorders Research